Good day, welcome to the Cencora Incorporated Annual Meeting. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Bob Mauch. Please go ahead, sir. Good afternoon, ladies and gentlemen. I'm Bob Mauch, President and CEO of Cencora. On behalf of the company's board and management, I'm pleased to welcome all of you to this annual meeting of shareholders. The chair of Cencora's board of directors has requested that I serve as chair of this annual meeting, and Korey Pirouz, who is secretary of the corporation, will act as secretary of the meeting. At this time, I call the meeting to order and ask that the secretary review the rules of conduct and the meeting agenda. Thank you, Mr. Mauch. The agenda and rules of conduct for this annual meeting are posted in the virtual shareholder meeting website. We will conduct the business portion of the meeting first and answer appropriate questions at the end of the meeting. If you wish to ask a question, please submit it through the virtual shareholder meeting website using the submission form. Though we may not be able to answer every question, we will do our best to provide a response to as many as possible. The chair of the meeting has asked me to be responsible for enforcing compliance with the agenda and rules of conduct during the course of this meeting. Please note that this meeting is being recorded. No one attending via the webcast or telephone is permitted to use any recording or rebroadcasting device. As mentioned in the company's proxy statement, participating today are representatives of Ernst & Young, the company's independent registered public accounting firm. The representatives will respond to any questions that arise during the discussion period that should be addressed to Ernst & Young. Also participating in today's meeting is the company's board of directors. In addition, we are being assisted today by Tony Carideo of Broadridge Financial Solutions. Mr. Carideo will serve as our inspector of election for the meeting and will tabulate proxies and ballots. Our agenda for today's meeting will be as follows. We will begin with my secretary's report on the mailing of the notice of this meeting and the presence of a quorum. We will then proceed with the following action items: the election of 11 directors, an advisory vote to approve the fiscal year 2025 compensation of the company's named executive officers, and the ratification of the appointment of Ernst & Young as the company's independent registered public accounting firm for fiscal year 2026. No other business was specified in the notice of the meeting or brought by a shareholder in accordance with the company's bylaws, and the board of directors has determined not to bring any other matters before the meeting. After the voting on the reference matters, there will be a business presentation. After the presentation, we will answer shareholders' questions. I will now report on the mailing of the notice of this meeting and the presence of a quorum. This meeting is held pursuant to a printed notice mailed on January 22nd, 2026 to shareholders of record as of the close of business on January 12th, 2026. All documents concerning the call and notice of the company meeting will be filed with the records of the company. A list of shareholders entitled to vote at this meeting has been available at the company's headquarters for the past 10 days and is available for examination by any shareholder wishing to do so. As of the close of business on January 12th, 2026, which is the record date for this meeting, there were 194,526,076 shares of the company's common stock outstanding. Majority of the outstanding shares of common stock are represented at this meeting, either present via virtual participation or by proxy. Because the majority of the outstanding shares of the company's common stock are represented at this meeting, a quorum exists. This meeting is duly organized and sufficiently constituted to transact business. As indicated, Mr. Carideo has been appointed as Inspector of Election. He has been sworn into office, and the proxies have been delivered to him. The polls for voting on all matters are hereby opened at this time. The first order of business is the election of 11 directors to serve for a one-year term. The director nominees are Werner Baumann, Frank Clyburn, Ellen Cooper, Mark Durcan, Lon Greenberg, Dr. Lorence Kim, Bob Mauch, Dr. Redonda Miller, Dennis Nally, Lori Ryerkerk, and Lauren Tyler. Our proxy statement sets forth a brief biography of each of the director nominees. The second order of business is an advisory vote to approve the fiscal year 2025 compensation of the company's named executive officers. The third order of business is a ratification of the appointment of Ernst & Young as the company's independent registered public accounting firm for fiscal year 2026. The board of directors recommends a vote for the election of each of the director nominees set forth in the first order of business and in favor of the second and third orders of business. If you desire to vote online during this meeting, you can do so via the web portal. If you have previously voted by proxy, you do not need to vote today unless you wish to change your vote. If you do vote via the web portal, it will operate to revoke any previously granted proxy. The polls for voting on the matters before this meeting are hereby closed. I have been informed that the Inspector of Election has examined all proxies and ballots, and I now ask Mr. Carideo to report the results of the voting. Operator, please take Mr. Carideo off mute. Thank you. Each of the director nominees has received the affirmative votes of a majority of the votes cast. The proposal to approve on an advisory basis the fiscal year 2025 compensation of the company's named executive officers, as described in the proxy statement, has received the affirmative votes of a majority of the votes present via virtual participation or by proxy and entitled to vote. The proposal to ratify the appointment of Ernst & Young as the company's independent registered public accounting firm for fiscal year 2026 has received the affirmative votes of a majority of the shares present via virtual participation or by proxy and entitled to vote. Thank you, Mr. Carideo, for that report. Congratulations to Werner, Frank, Ellen, Mark, Lon, Lorence, Redonda, Dennis, Lori, and Lauren on being reelected as directors. We will now move on to the business presentation. Thank you for joining our annual meeting of shareholders, and we appreciate your investment in our business. See our cautionary note on forward-looking statements. For more details, please refer to our investor relations website. Cencora is a purpose-driven, leading healthcare company, united in our responsibility to create healthier futures. With a foundation in pharmaceutical distribution, with complementary higher margin, high growth businesses that drive value across the healthcare landscape. Cencora is responsible for ensuring patients have the medications they need when and where they need them. We distribute over 1 billion medications annually to thousands of stakeholders and work to ensure the pharmaceutical supply chain remains safe, secure, and efficient. Over the years, Cencora has been focused on building an extensive offering and specialty that serves both provider customers and manufacturers. Our solutions support manufacturers bringing products to market through the clinical trial support, research capabilities, specialized logistics, and 3PL services. For providers, we partner with leading specialists across channels to ensure patients can receive high- caliber care in their local communities. Our differentiated capabilities underpin our strong results. In fiscal 2025, we were pleased to deliver adjusted operating income and adjusted diluted EPS growth of 16%. Cencora is incredibly well-positioned, and that is due to our strategy and team members' execution. We're guided by our pharmaceutical-centric strategy and are focused on amplifying our execution through four strategic drivers: digital transformation, productivity, growth-oriented investments, and talent and culture. Our strategic drivers enable us to win in our three prioritized areas of growth. Leading with market leaders who require partners that operate in the most productive and advanced manner. Strengthening our leadership and specialty through our focus on growth-oriented investments. Contributing to pharmaceutical outcomes by harnessing the data we generate to derive valuable insights for manufacturers on patient outcomes and market access. Recently, we've made meaningful progress to advance our strategy, aligned with our growth priorities and powered by our strategic drivers. We closed our acquisition of RCA in January 2025 and have been very pleased with the MSO's performance so far as its clinical trial capabilities are providing differentiated value to pharma and attract physicians to the RCA platform. We're excited to announce we completed our acquisition of OneOncology in February 2026. The platform has demonstrated significant growth since our initial investment, and our partnership will support the needs of independent community physicians. Cencora has committed $1 billion in investments through 2030 to strengthen our infrastructure, ensuring we are equipped to meet the growing demand of pharmaceuticals. We continue to expand our footprint and our global specialty logistics and 3PL businesses to partner with biopharma innovators across the globe as they bring their products to market. We're also pleased to have raised our long-term guidance. Cencora has been driving executional excellence and performing above our long-term targets, and we will continue our focus on creating value for all of our stakeholders. In closing, Cencora is positioned to continue building on our value for all stakeholders. As our strong foundation will advance the healthcare industry, we are strengthening our solutions to lead with leaders as the industry grows and evolve, and we are building on our legacy of delivering on our long-term guidance and generating attractive shareholder returns. Thank you, Mr. Mauch. At this time, we'll move on to the question and answer portion of the agenda. There are no questions that have been submitted by shareholders.